Navigation Links
Memory Study Enrolling Participants Evaluating Memory Loss Vitamin

Quincy Bioscience has announced enrollment is underway for a memory loss study evaluating the impact of Prevagen® on cognitive function. Men and women aged 40 years and older who are experiencing memory loss and can travel to Madison, WI area are encouraged to apply at Madison Memory Study.

(Vocus) February 1, 2010 -- Quincy Bioscience is seeking men and women 40 years and older who are experiencing memory loss to enroll in a study that will evaluate the effects of the brain health supplement Prevagen® on cognitive function. The Prevagen Memory Study is a randomized placebo-controlled, double-blind study that will require five (5) visits for cognitive testing during the three (3) month study period. The impact of Prevagen on brain cell protection will be evaluated using computer-based cognitive testing software. The study is sponsored by Quincy Bioscience, the manufacturer of Prevagen®.

Quincy Bioscience is pleased to collaborate with Cogstate Ltd., a leading cognitive testing software company based in Melbourne, Australia. Cogstate’s proprietary computer-based testing software will be utilized to assess the effect of Prevagen on cognitive performance. “We are excited to utilize the testing software from Cogstate for the Madison Memory Study,” says Quincy Bioscience president Mark Underwood. “Cogstate is an industry leader with extensive research validating the use of its software tools for measuring cognitive effects.”

Prevagen® is the first and only product to use the active ingredient apoaequorin, a calcium-binding protein discovered in jellyfish. In university studies, Prevagen® was proven to protect brain cells.* First launched in in September of 2007, tens of thousands of people have taken Prevagen®.

Interested candidates who are able to travel to Madison, WI may visit Madison Memory Study to apply or call (608) 237-3170 for more information about the study.

Quincy Bioscience is a biotechnology company based in Madison, Wisconsin. Quincy Bioscience is focused on the discovery, development and commercialization of novel compounds to fight the aging process. The company's products focus on restoring calcium balance related to neurodegenerative disorders and other destructive age-related mechanisms. Quincy Bioscience is developing health applications of the jellyfish protein apoaequorin for dietary supplement and pharmaceutical products. The company’s first product, Prevagenwas launched in the fall of 2007 and is intended to supplement the loss of critical calcium-binding proteins depleted in the normal course of healthy aging.

  • These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
2. Scientists synthesize memory in yeast cells
3. Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster
4. Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster
5. Scientists synthesize memory in yeast cells
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. BioMedical Enterprises, Inc. (BME) Receives FDA Clearance for Spine Use of Its Memory Metal Implants
8. ASU researchers improve memory devices using nanotech
9. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
10. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
11. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
Post Your Comments:
Related Image:
Memory Study Enrolling Participants Evaluating Memory Loss Vitamin
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology:
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:4/28/2016)... and BANGALORE, India , April 28, ... Systems, a product subsidiary of Infosys (NYSE: INFY ... announced a global partnership that will provide end ... use mobile banking and payment services.      (Logo: ... key innovation area for financial services, but it also plays ...
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
Breaking Biology News(10 mins):